Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14029827 | 0.92 | CACNA1B (0.43) | MAPK1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14029825 | 0.92 | CACNA1B (0.49) | MAPK1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14767967 | 0.89 | KMT2A (0.51) | MAPK1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14029826 | 0.88 | MAPK1 (0.42) | MAPK1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14029824 | 0.84 | POLB (0.40) | MAPK1KMT2AMAPTALDH1A1 | |
| SCHEMBL14924932 | 0.82 | MAPT (0.51) | MAPK1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14767971 | 0.81 | KMT2A (0.54) | MAPK1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5003467 | 0.77 | CACNA1B (0.48) | MAPK1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5002691 | 0.73 | MAPK1 (0.51) | MAPK1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14924985 | 0.73 | NPC1 (0.48) | MAPK1KMT2AMAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399464-B2 | using a triazole compound; anticancer agent | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269218-A1 | Novel Hsp90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | MAPK1 512/4885KMT2A 3396/4885MAPT 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.